Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationDepreciation & Amortization (IS)Depreciation ExpenseEBIATOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Shares Issued
Ratios

InMed Pharmaceuticals (INM) Depreciation Expense (2022 - 2025)

Historic Depreciation Expense for InMed Pharmaceuticals (INM) over the last 4 years, with Q2 2025 value amounting to $12206.0.

  • InMed Pharmaceuticals' Depreciation Expense rose 12437.5% to $12206.0 in Q2 2025 from the same period last year, while for Jun 2025 it was $50204.0, marking a year-over-year increase of 515.91%. This contributed to the annual value of $50204.0 for FY2025, which is 515.69% up from last year.
  • InMed Pharmaceuticals' Depreciation Expense amounted to $12206.0 in Q2 2025, which was up 12437.5% from $12203.0 recorded in Q1 2025.
  • In the past 5 years, InMed Pharmaceuticals' Depreciation Expense ranged from a high of $14242.0 in Q4 2023 and a low of $5440.0 during Q2 2024
  • Moreover, its 4-year median value for Depreciation Expense was $12209.0 (2024), whereas its average is $11773.0.
  • As far as peak fluctuations go, InMed Pharmaceuticals' Depreciation Expense plummeted by 5788.17% in 2024, and later surged by 12437.5% in 2025.
  • Quarter analysis of 4 years shows InMed Pharmaceuticals' Depreciation Expense stood at $8056.0 in 2022, then skyrocketed by 76.79% to $14242.0 in 2023, then decreased by 14.27% to $12209.0 in 2024, then decreased by 0.02% to $12206.0 in 2025.
  • Its Depreciation Expense stands at $12206.0 for Q2 2025, versus $12203.0 for Q1 2025 and $12209.0 for Q4 2024.